Kim Raineri and Andrés Bratt-Leal, PhD, presented at Phacilitate Advanced Therapies Week

Aspen Neuroscience’s Co-Founder and Senior Vice President of Research and Development, Andrés Bratt-Leal, PhD, and Chief Technology Officer, Kim Raineri, presented at the Advanced Therapies Week session, “Cell and Gene Therapy for Neurological Indications” on Friday, January 20th.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.